Clinical Trial: Gemcitabine in NK/T Cell Lymphoma
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma
Brief Summary: We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen
Detailed Summary:
Sponsor: Samsung Medical Center
Current Primary Outcome: Overall response rate [ Time Frame: 2012-May ]
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Samsung Medical Center
Dates:
Date Received: August 6, 2012
Date Started: August 2012
Date Completion:
Last Updated: February 11, 2013
Last Verified: August 2012